Published in Eur J Med Res on August 08, 2011
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens. Clin Pharmacol Ther (2013) 1.03
IL28B polymorphism and cytomegalovirus predict response to treatment in Egyptian HCV type 4 patients. World J Gastroenterol (2013) 0.92
Lower liver-related death in African-American women with human immunodeficiency virus/hepatitis C virus coinfection, compared to Caucasian and Hispanic women. Hepatology (2012) 0.91
Impact of host IL28B rs12979860, rs8099917 in interferon responsiveness and advanced liver disease in chronic genotype 3 hepatitis C patients. PLoS One (2014) 0.80
Association of IFNL3 and IFNL4 polymorphisms with liver-related mortality in a multiracial cohort of HIV/HCV-coinfected women. J Viral Hepat (2015) 0.77
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 16.40
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology (2003) 10.25
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (2006) 10.18
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med (2004) 9.72
Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis (2001) 5.27
Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet (2003) 4.88
Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol (2008) 4.21
Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut (2007) 3.58
IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology (2010) 3.57
Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology (2010) 3.26
An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology (2010) 2.87
Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology (2010) 2.83
Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology (2010) 2.68
Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology (2007) 2.39
Interferon-lambda serum levels in hepatitis C. J Hepatol (2010) 2.28
Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol (2005) 2.27
Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol (2008) 2.05
Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS (2007) 1.92
IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J Hepatol (2010) 1.86
Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages. J Virol (2009) 1.74
Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology (2009) 1.64
Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection. Gastroenterology (2009) 1.58
Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis (2010) 1.58
Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology (2009) 1.47
Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers. J Viral Hepat (2009) 1.02
Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients. Hepatology (2007) 0.92
Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: a meta-analysis of the risk factors. Hepatology (2010) 0.88
Transient elastography discloses identical distribution of liver fibrosis in chronic hepatitis C between HIV-negative and HIV-positive patients on HAART. Eur J Med Res (2010) 0.86
There is no difference in hepatic fibrosis rates of patients infected with hepatitis C virus and those co-infected with HIV. Braz J Med Biol Res (2007) 0.85
Applicability and variability of liver stiffness measurements according to probe position. World J Gastroenterol (2009) 0.84
Overestimation of liver fibrosis staging using transient elastography in patients with chronic hepatitis C and significant liver inflammation. Antivir Ther (2009) 0.83
Correlation of transient elastography with APRI and FIB-4 in a cohort of patients with congenital bleeding disorders and HCV or HIV/HCV coinfection. Haemophilia (2010) 0.77
[Causes of death in HIV patients]. MMW Fortschr Med (2009) 0.76
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03
Shock-wave lithotripsy of gallbladder stones. The first 175 patients. N Engl J Med (1988) 5.53
Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet (2003) 4.88
Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet (2005) 3.97
Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in hepatitis C. Gastroenterology (2002) 3.96
Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data. Hepatology (2014) 3.30
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology (2008) 3.14
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology (2010) 3.02
Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry (1999) 2.90
A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology (2010) 2.78
Fragmentation of gallstones by extracorporeal shock waves. N Engl J Med (1986) 2.76
Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology (2006) 2.68
Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases. Hepatology (2003) 2.68
Late presentation of HIV infection: a consensus definition. HIV Med (2011) 2.67
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology (2006) 2.62
Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scand J Gastroenterol (2002) 2.54
HIV and hepatitis C virus co-infection. Lancet Infect Dis (2004) 2.35
A citric acid solution is an optimal test drink in the 13C-urea breath test for the diagnosis of Helicobacter pylori infection. Gut (1997) 2.32
Interferon-lambda serum levels in hepatitis C. J Hepatol (2010) 2.28
p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut (2009) 2.20
Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Ann Intern Med (2012) 2.14
Polymorphisms in melanoma differentiation-associated gene 5 link protein function to clearance of hepatitis C virus. Hepatology (2015) 2.11
Topographic association between active gastritis and Campylobacter pylori colonisation. J Clin Pathol (1989) 2.09
Intrahepatic IL-8 producing Foxp3⁺CD4⁺ regulatory T cells and fibrogenesis in chronic hepatitis C. J Hepatol (2013) 2.03
[S3-Guidelines Conference "Colorectal Carcinoma" 2004]. Z Gastroenterol (2004) 2.03
Clostridium difficile infection in patients with neutropenia. Clin Infect Dis (2001) 2.00
Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C. Gut (2005) 1.99
Acute hepatitis A in haemophiliacs. Lancet (1992) 1.96
Evaluation of an ultrasound-guided technique for central venous access via the internal jugular vein in 493 patients. Support Care Cancer (2002) 1.95
The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era. Clin Infect Dis (2013) 1.91
T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus--positive blood donors without viremia. Hepatology (1996) 1.88
Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment. J Thromb Haemost (2011) 1.73
Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost (2007) 1.72
Difference in expression of Helicobacter pylori gastritis in antrum and body. Gastroenterology (1992) 1.70
Dormia baskets impacted in the bile duct: release by extracorporeal shock-wave lithotripsy. Endoscopy (1995) 1.70
Increased frequency of the HLA-DR15 (B1*15011) allele in German patients with self-limited hepatitis C virus infection. Eur J Clin Invest (1999) 1.68
Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic cholestasis of pregnancy. Gut (2008) 1.68
The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol (2008) 1.65
Comparison of capsule endoscopy and magnetic resonance imaging for the detection of polyps of the small intestine in patients with familial adenomatous polyposis or with Peutz-Jeghers' syndrome. Endoscopy (2004) 1.64
Gallstones: pathogenesis. Lancet (1991) 1.64
Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. J Hepatol (2011) 1.62
Inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) expression in fulminant hepatic failure. J Hepatol (2002) 1.60
Natural killer p46High expression defines a natural killer cell subset that is potentially involved in control of hepatitis C virus replication and modulation of liver fibrosis. Hepatology (2012) 1.60
Gallstone recurrence after shock-wave therapy. Gastroenterology (1994) 1.59
Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis (2013) 1.58
Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer (2003) 1.57
Phenotypic characterization of Lith genes that determine susceptibility to cholesterol cholelithiasis in inbred mice: soluble pronucleating proteins in gallbladder and hepatic biles. J Hepatol (2001) 1.55
Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann Oncol (2007) 1.52
Characterization of duplication breakpoints in the factor VIII gene. J Thromb Haemost (2010) 1.52
Comparative study of NK cell-mediated cytotoxicity using radioactive and flow cytometric cytotoxicity assays. J Immunol Methods (2005) 1.51
Long-term results and prognostic factors in the treatment of achalasia with botulinum toxin. Endoscopy (2002) 1.51
Low-molecular weight proteins as markers for glomerular filtration rate. Clin Chem (2001) 1.50
The HLA-A2 restricted T cell epitope HCV core 35-44 stabilizes HLA-E expression and inhibits cytolysis mediated by natural killer cells. Am J Pathol (2005) 1.48
Bleeding complications after percutaneous liver biopsy. An analysis of risk factors. Digestion (2003) 1.48
Prediction of variceal hemorrhage in cirrhosis: a prospective follow-up study. Gastroenterology (1991) 1.47
Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma. World J Gastroenterol (2001) 1.47
Regulation of CC chemokine receptor 5 in hepatitis G virus infection. AIDS (2003) 1.47
Comparison of portal vein velocity and the hepatic venous pressure gradient in assessing the acute portal hemodynamic response to propranolol in patients with cirrhosis. Am J Gastroenterol (2000) 1.46
[Symptoms, tumor stage and primary treatment in patients with colorectal carcinoma]. Dtsch Med Wochenschr (1997) 1.46
Genotypic interaction and gender specificity of common genetic variants in the p53/mdm2 network in Crohn's disease. Digestion (2010) 1.45
[Fatty liver and increased serum lactate in a woman with HIV]. Dtsch Med Wochenschr (2003) 1.44
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol (2012) 1.44
Surgical intervention following fragmentation of gallstones by extracorporeal shock waves. World J Surg (1989) 1.42
[Fecal incontinence]. Internist (Berl) (2000) 1.42
Serum bile acids: physiology and clinical relevance. Eur J Gastroenterol Hepatol (1995) 1.41
Serological and virological markers of human parvovirus B19 infection in sera of hemophiliacs. Thromb Haemost (1994) 1.40
In silico calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene. Haemophilia (2013) 1.40
[Lipid metabolism disorders in pregnancy]. Dtsch Med Wochenschr (2008) 1.39
[Therapy-refractory thrombocytopenia in chronic hepatitis C]. Z Gastroenterol (2000) 1.39
[Severe refractory pulmonary hypertension after liver transplantation for hepatitis C liver cirrhosis]. Z Gastroenterol (2006) 1.39
[The therapy of the hepatorenal syndrome in liver cirrhosis]. Dtsch Med Wochenschr (1999) 1.39
[Treatment options for vascular ectasias of the gastric antrum (watermelon stomach)]. Dtsch Med Wochenschr (2001) 1.38
IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Med (2011) 1.36
Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis. Biomed Pharmacother (1999) 1.33
Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology (2001) 1.32
Mixed-strain infection with a drug-sensitive and multidrug-resistant strain of Mycobacterium tuberculosis. Lancet (1995) 1.32
Pathogenesis and pathophysiology of anemia in HIV infection. Ann Hematol (1998) 1.29
A novel minimal-size vector (MIDGE) improves transgene expression in colon carcinoma cells and avoids transfection of undesired DNA. Mol Ther (2001) 1.28
Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol (2000) 1.28
Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. HIV Med (2013) 1.28
Definitions, methodology and therapeutic strategies in portal hypertension. A Consensus Development Workshop, Baveno, Lake Maggiore, Italy, April 5 and 6, 1990. J Hepatol (1992) 1.27
Fecal elastase test: evaluation of a new noninvasive pancreatic function test. Am J Gastroenterol (1995) 1.27
Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology (2001) 1.25
The Munich Gallbladder Lithotripsy Study. Results of the first 5 years with 711 patients. Ann Intern Med (1991) 1.23
Mechanisms of extrahepatic vasodilation in portal hypertension. Gut (2008) 1.23
Phenotypic characterization of lith genes that determine susceptibility to cholesterol cholelithiasis in inbred mice. Pathophysiology Of biliary lipid secretion. J Lipid Res (1999) 1.22
Search for intrafamilial transmission of hepatitis C virus in hemophilia patients. Blood (1993) 1.22
Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J Immunother (2001) 1.21
S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII). Z Gastroenterol (2010) 1.20
Calculation of glomerular filtration rate based on cystatin C in cirrhotic patients. Nephrol Dial Transplant (2005) 1.20
Decreased frequency of HCV core-specific peripheral blood mononuclear cells with type 1 cytokine secretion in chronic hepatitis C. J Hepatol (1999) 1.20
Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus. Eur J Immunol (2004) 1.20
A retrospective analysis of 3 year's experience of an interdisciplinary approach to gallstone disease including shock-waves. Ann Surg (1988) 1.19
Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Med (2011) 1.19
Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology (1992) 1.19
Shock-wave therapy of gastric outlet syndrome caused by a gallstone. Gastroenterology (1989) 1.19